Aurobindo Pharma gets USFDA nod for Perampanel Tablets. Aurobindo Pharma received final USFDA approval for Perampanel Tablets in six strengths, bioequivalent to Fycompa®. The market is valued at US$67 million. Manufactured at APL Healthcare's Unit-IV, launch is planned in Q3 FY2027. The drug treats partial-onset and primary generalised tonic-clonic seizures. Aurobindo now holds 599 ANDA approvals.